EPCAM and ovarian carcinoma: Several bispecific antibodies such as Catumaxomab, MT110 and M701 have been designed to simultaneously bind EPCAM and CD3, to induce a specific T-cell-mediated immune response against ovarian cancer cells (Li et al., 2023).